Related Experiment Videos
Summary
Elevated carcinoembryonic antigen (CEA) levels, along with other biomarkers, can detect metastatic disease. Higher CEA levels correlate with poorer treatment response in metastatic cancer patients.
Area of Science:
- Oncology
- Biomarker Discovery
Background:
- Plasma carcinoembryonic antigen (CEA) is a known tumor marker.
- Limited data exists on its combined utility with other biomarkers for detecting metastatic disease and predicting treatment outcomes.
Purpose of the Study:
- To evaluate the diagnostic and prognostic value of CEA, human chorionic gonadotropin (hCG), polyamines, and minor nucleosides in patients with various stages of cancer.
- To assess the correlation between CEA levels and treatment response in metastatic disease.
Main Methods:
- Measurement of plasma CEA, hCG, three polyamines, and three minor nucleosides in preoperative, postoperative, and metastatic cancer patient cohorts.
- Sequential monitoring of CEA levels in patients with metastatic disease.
- Analysis of CEA levels in relation to treatment response rates and time to treatment failure.
Main Results:
- Elevated CEA was found in 70.9% of metastatic patients, with detection rates significantly enhanced (up to 98.6%) when combined with other biomarkers.
- Sequential CEA levels paralleled clinical disease course in metastatic patients.
- Pre-therapy CEA levels >5 ng/ml were associated with lower response rates and shorter treatment failure times, an effect amplified by elevated hCG.
Conclusions:
- Combined biomarker analysis, including CEA, significantly improves metastatic cancer detection rates.
- Pre-treatment CEA levels serve as a prognostic indicator for treatment response and disease progression in metastatic cancer.
- Hepatic and osseous metastases show a higher incidence of CEA elevation compared to pulmonary or soft tissue involvement.